Adapsyn Bioscience Inc.: federal grants and contributions: 6 agreements; $1.3M value; 2 departments; 4 programs.
Assay record ASY-CA-18Q5QH90JT · Cite as: Assay Systems, “Adapsyn Bioscience Inc.: federal grants and contributions”, https://assay-systems.com/register/ca/grants/r/adapsyn-bioscience-inc/
Adapsyn’s proprietary drug discovery platform will be applied to the screening of bacteria to discover neuro- and immunomodulatory small molecules to develop therapeutic agents for the treatment of childhood neuropsychiatric disorders.
RRRF funding will be used to support Recipients to address the impacts of the COVID-19 pandemic.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
The funding provided by the IAP program is intended to assist innovative small and medium-sized enterprises in the start-up phase that cannot access existing commercial support related to COVID-19.
Bacterial strains from the human microbiome will be screened for the production of secondary metabolites with the potential to influence the human nervous and immune systems, for potential application in childhood neuropsychiatric disorders.
The funding provided from the Innovation Assistance Program is to assist innovative, early-stage small- and medium-sized enterprises that are unable to access existing COVID-19 business support.
All grants from Federal Economic Development Agency for Southern Ontario
Contains information licensed under the Open Government Licence – Canada. Source: Government of Canada proactive disclosure of grants and contributions (open.canada.ca, dataset 432527ab-7aac-45b5-81d6-7597107a7013), 1,327,352 rows as published, collapsed to one agreement per agreement number (per reference number where none is given) at its latest amendment, which carries the full agreement value. Years are the agreement start year. Agreements with individuals are counted but not named.